GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioNxt Solutions Inc (OTCPK:BNXTF) » Definitions » EV-to-EBITDA

BioNxt Solutions (BioNxt Solutions) EV-to-EBITDA : -9.43 (As of Jun. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioNxt Solutions EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioNxt Solutions's enterprise value is $31.96 Mil. BioNxt Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.39 Mil. Therefore, BioNxt Solutions's EV-to-EBITDA for today is -9.43.

The historical rank and industry rank for BioNxt Solutions's EV-to-EBITDA or its related term are showing as below:

BNXTF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.68   Med: -6.03   Max: -2.55
Current: -9.57

During the past 6 years, the highest EV-to-EBITDA of BioNxt Solutions was -2.55. The lowest was -18.68. And the median was -6.03.

BNXTF's EV-to-EBITDA is ranked worse than
100% of 714 companies
in the Drug Manufacturers industry
Industry Median: 14.065 vs BNXTF: -9.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), BioNxt Solutions's stock price is $0.27516. BioNxt Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.036. Therefore, BioNxt Solutions's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


BioNxt Solutions EV-to-EBITDA Historical Data

The historical data trend for BioNxt Solutions's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNxt Solutions EV-to-EBITDA Chart

BioNxt Solutions Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -7.39 -7.35 -4.57 -5.04 -8.73

BioNxt Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.04 -5.90 -3.83 -8.73 -12.34

Competitive Comparison of BioNxt Solutions's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNxt Solutions's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioNxt Solutions's EV-to-EBITDA falls into.



BioNxt Solutions EV-to-EBITDA Calculation

BioNxt Solutions's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=31.963/-3.39
=-9.43

BioNxt Solutions's current Enterprise Value is $31.96 Mil.
BioNxt Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioNxt Solutions  (OTCPK:BNXTF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioNxt Solutions's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.27516/-0.036
=At Loss

BioNxt Solutions's share price for today is $0.27516.
BioNxt Solutions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.036.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


BioNxt Solutions EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioNxt Solutions's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNxt Solutions (BioNxt Solutions) Business Description

Traded in Other Exchanges
Address
1820 Fir Street, Suite 270, Vancouver, BC, CAN, V6J 3B1
BioNxt Solutions Inc is a cannabis company engaged in developing analytical testing, processing, and formulation capability in Canada. It is also engaged in research, cultivation, extraction, import, distribution, and manufacturing in Germany. The products of the company include Drug Delivery, Point-of-Care Diagnostics, and Psychedelics.